FDA薬品安全委員会:pioglitazoneの膀胱癌リスク増加への疑念

At this time, FDA has not concluded that Actos increases the risk of bladder cancer.
Its review is ongoing, and the Agency will update the public when it has additional information.

FDA Drug Safety Communication: Ongoing Safety Review of Actos (pioglitazone) and Potential Increased Risk of Bladder Cancer After Two Years Exposure
http://www.fda.gov/Drugs/DrugSafety/ucm226214.htm


あえて、アクトスとは書かなかった・・・

by internalmedicine | 2010-09-21 14:59 | 糖尿病・肥満  

<< 肥満ダイエット中、毎日ミルク・... “less is more”:... >>